Nos publications

Impact of gastric phase simulation on the in vitro lipolysis of lipid-based formulations containing ticagrelor and fenofibrate

  • Poster

AAPS - nov 2025

Manon Rossano, Arnaud Bourderi-Cambon, Stéphanie Chevrier, Diane Schneider, Philippe Caisse

The study examines how adding a simulated gastric phase before intestinal lipolysis affects the solubilization of two lipophilic drugs, highlighting that gastric digestion improves in vitro prediction of pharmacokinetics and formulation discrimination.

Assessing the performance of lipids as surfactants to enhance the release profile of a model BCS class IV compound from ASD

  • Poster

AAPS - nov 2025

Karan Siyodia, Masumi Dave, Seth Forster, Graciela Terife

This study aimed to develop Amorphous Solid Dispersions (ASDs) of anacetrapib, a lipophilic BCS class IV drug, using Hot Melt Extrusion (HME) with lipid-based excipients as surfactants to improve dissolution. A secondary goal was to establish a robust method for incorporating solid or semi-solid excipients into powder blends for HME without requiring specialized feeding ports.

Capryol® 90 is an efficacious intestinal absorption enhancer for insulin in vivo when combined other excipients

  • Scientific publication

International Journal of Pharmaceutics - déc 2025

Fiona McCartney, Philippe Caisse, Camille Dumont, David Brayden

This article is the third of the series, written in the context of our collaboration with the University College of Dublin and its professors Fiona McCartney and David Brayden. In this study, the authors focused on Capryol® 90 to demonstrate its intestinal permeation ability in vivo, with insulin as model API.

Improving in vitro–in vivo correlation (IVIVC) for lipid-based formulations: overcoming challenges and exploring opportunities

  • Scientific publication

Pharmaceutics - 2025

Arnaud Bourderi-Cambon, Khaled Fadhlaoui, Ghislain Garrait, Emmanuelle Lainé, Imen Dhifallah, Manon Rossano, Philippe Caisse and Eric Beyssac

In this article, we review the in vitro-in vivo correlation methods for lipid-based formulations to pave the way for more effective and adaptable methods.

Innovative bi-gel textures start with the right process

  • Poster

5th Conference on Innovation in Drug Delivery - oct 2025

Elise Dauphin-Chanard, Delphine Pélisson, Manon Rossano, Emilie Leccia, Jean Doucet

In this poster co-written with Novitom, we focus on bi-gels manufacturing process and describe the key process parameters and their impact on the bi-gel structure.

Formulation optimization and real-time size monitoring in the semi-continuous production of edaravone-loaded lipid-based nanocarriers using the Microfluidizer® technology: Part 2

  • Scientific publication

European Journal of Pharmaceutical Sciences - sep 2025

Christina Glader, Ramona Jeitler, Yan Wang, Jesus Alberto Afonso Urich, Carolin Tetyczka, Philippe Caisse, Steve Mesite, Vanessa Bourgeaux, Johannes Khinast, Eva Roblegg

In this article, which stems from our participation in the NanoFacT consortium, the authors evaluate the optimization of the production of lipid nanocarriers loaded with edaravone using Microfluidizer® technology. Lipid nanocarriers manufactured in the study used Precirol® ATO 5 or Gelucire® 43/01 as solid lipids, combined with Labrafac™ Lipophile WL 1349 or Capryol® 90 as liquid lipids.

Leveraging the advantages of lipid excipients in tablets: Gelucire® 48/16 as bioenhancer for fenofibrate

  • Poster

8th International Symposium on Solid Oral Dosage Forms - sep 2025

Claudia Gama, Elise Dauphin-Chanard, Jean-Michel Girard, Cédric Miolane, Malaury Ducros,, Philippe Caisse

In this poster, we highlighted the use of grinded Gelucire® 48/16 in a wet granulation process, for bioavailability enhancement. With fenofibrate as API model, we showed a drug release profile similar to the commercial reference.

Expanding your tablet lubrication toolbox: addressing common challenges

  • Whitepaper

Contract Pharma - jui 2025

Nick DiFranco

In this new whitepaper, we explain what are the key differences between common families of lubricants, then explain the common hurdles encountered in lubrication before displaying how our Compritol® 888 ATO gets round those difficulties.

Ticagrelor amorphous solid dispersion tablets: formulation with Gelucire® 48/16

  • Poster

CRS - jui 2025

Elsa Gattefossé, Diane Schneider, Cédric Miolane, Karan Siyodia, Philippe Caisse

This study consisted in the formulation of ticagrelor amorphous solid dispersion (ASD) tablets using Gelucire® 48/16. Results showed a better ticagrelor release from tablets obtained with ASD extrudates containing a ternary mixture (API + polymer + Gelucire® 48/16).